Abbott Laboratories stock could rise 40%+ by 2027, driven by strong medical devices growth and Exact Sciences acquisition.

Abbott Laboratories has seen a strong rally since May, supported by growth in its core Medical Devices segment and the recent acquisition of Exact Sciences. The company holds an A+ credit rating with a stable outlook, and its shares currently trade at a 26% discount to the updated fair value estimate. Analysts project the stock could deliver over 40% upside by June 2027 and annual total returns of 16% through 2031, making it a compelling dividend growth investment opportunity.